ATE510831T1 - Hydrierte benzoäcüthiophenderivate als immunmodulatoren - Google Patents

Hydrierte benzoäcüthiophenderivate als immunmodulatoren

Info

Publication number
ATE510831T1
ATE510831T1 AT06727679T AT06727679T ATE510831T1 AT E510831 T1 ATE510831 T1 AT E510831T1 AT 06727679 T AT06727679 T AT 06727679T AT 06727679 T AT06727679 T AT 06727679T AT E510831 T1 ATE510831 T1 AT E510831T1
Authority
AT
Austria
Prior art keywords
benzocethiophene
hydrogenated
derivatives
immune modulators
modulators
Prior art date
Application number
AT06727679T
Other languages
English (en)
Inventor
Martin Bolli
David Lehmann
Boris Mathys
Claus Mueller
Oliver Nayler
Joerg Velker
Thomas Weller
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Application granted granted Critical
Publication of ATE510831T1 publication Critical patent/ATE510831T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/72Benzo[c]thiophenes; Hydrogenated benzo[c]thiophenes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/78Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AT06727679T 2005-03-23 2006-03-20 Hydrierte benzoäcüthiophenderivate als immunmodulatoren ATE510831T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2005003071 2005-03-23
PCT/IB2006/050845 WO2006100631A1 (en) 2005-03-23 2006-03-20 Hydrogenated benzo (c) thiophene derivatives as immunomodulators

Publications (1)

Publication Number Publication Date
ATE510831T1 true ATE510831T1 (de) 2011-06-15

Family

ID=36592888

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06727679T ATE510831T1 (de) 2005-03-23 2006-03-20 Hydrierte benzoäcüthiophenderivate als immunmodulatoren

Country Status (26)

Country Link
US (2) US7723378B2 (de)
EP (1) EP1863787B1 (de)
JP (1) JP5047941B2 (de)
KR (1) KR101382733B1 (de)
CN (1) CN101180290B (de)
AR (1) AR053452A1 (de)
AT (1) ATE510831T1 (de)
AU (1) AU2006226018B2 (de)
BR (1) BRPI0609515A8 (de)
CA (1) CA2602474C (de)
CY (1) CY1111767T1 (de)
DK (1) DK1863787T3 (de)
ES (1) ES2365747T3 (de)
HR (1) HRP20110613T1 (de)
IL (1) IL186148A (de)
MX (1) MX2007011670A (de)
MY (1) MY147949A (de)
NO (1) NO340192B1 (de)
NZ (1) NZ562562A (de)
PL (1) PL1863787T3 (de)
PT (1) PT1863787E (de)
RU (1) RU2412179C2 (de)
SI (1) SI1863787T1 (de)
TW (1) TWI402262B (de)
WO (1) WO2006100631A1 (de)
ZA (1) ZA200709088B (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4678139B2 (ja) * 2004-05-10 2011-04-27 トヨタ自動車株式会社 自動車の暖房制御システム
WO2006010379A1 (en) 2004-07-29 2006-02-02 Actelion Pharmaceuticals Ltd. Novel thiophene derivatives as immunosuppressive agents
BRPI0609668A2 (pt) * 2005-03-23 2011-10-18 Actelion Pharmaceuticals Ltd composto, composição farmacêutica, e, uso de um composto
KR20080002850A (ko) * 2005-03-23 2008-01-04 액테리온 파마슈티칼 리미티드 신규한 티오펜 유도체
AU2006260573A1 (en) * 2005-06-24 2006-12-28 Actelion Pharmaceuticals Ltd. Novel thiophene derivatives
AR057894A1 (es) 2005-11-23 2007-12-26 Actelion Pharmaceuticals Ltd Derivados de tiofeno
TWI404706B (zh) * 2006-01-11 2013-08-11 Actelion Pharmaceuticals Ltd 新穎噻吩衍生物
KR20080092385A (ko) 2006-01-24 2008-10-15 액테리온 파마슈티칼 리미티드 신규한 피리딘 유도체
CL2007002593A1 (es) * 2006-09-07 2008-06-13 Actelion Pharmaceuticals Ltd Compuestos derivados de 4-heteroaril-piridina; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como rechazo de organos transplantados, sindromes autoinmunes y cancer.
AR061841A1 (es) * 2006-09-07 2008-09-24 Actelion Pharmaceuticals Ltd Derivados de tiofen-oxadiazoles, agonistas del receptor s1p1/edg1, composiciones farmaceuticas que los contienen y usos como agentes inmunomoduladores.
SI2069335T1 (sl) * 2006-09-08 2013-04-30 Actelion Pharmaceuticals Ltd. Derivati piridin-3-ila kot imunomodulacijska sredstva
EP2069318B1 (de) * 2006-09-21 2012-09-12 Actelion Pharmaceuticals Ltd. Phenylderivate und ihre verwendung als immunmodulatoren
JP2010521450A (ja) * 2007-03-16 2010-06-24 アクテリオン ファーマシューティカルズ リミテッド S1p1/edg1受容体アゴニストとしてのアミノ−ピリジン誘導体
BRPI0820868A2 (pt) * 2007-12-10 2019-09-24 Actelion Pharmaceuticals Ltd composto de tiofeno fórmula(i), composição farmacêutica contendo o mesmo e uso deste para a prevenção ou tratamento de doenças ou disturbíos associados a um sistema imune ativado
PE20091339A1 (es) * 2007-12-21 2009-09-26 Glaxo Group Ltd Derivados de oxadiazol con actividad sobre receptores s1p1
EP2262799B1 (de) * 2008-03-06 2012-07-04 Actelion Pharmaceuticals Ltd. Pyridinverbindungen
SI2252609T1 (sl) * 2008-03-07 2013-07-31 Actelion Pharmaceuticals Ltd. Derivati piridin-2-ila kot imunomodulacijska sredstva
WO2009115954A1 (en) 2008-03-17 2009-09-24 Actelion Pharmaceuticals Ltd Dosing regimen for a selective s1p1 receptor agonist
HRP20161133T1 (hr) 2008-07-23 2016-12-02 Arena Pharmaceuticals, Inc. DERIVATI SUSPSTITUIRANE 1,2,3,4-TETRAHIDROCIKLOPENTA[b]INDOL-3-IL-OCTENE KISELINE KORISNI U LIJEČENJU AUTOIMUNIH I UPALNIH POREMEĆAJA
CN105816453B (zh) 2008-08-27 2021-03-05 艾尼纳制药公司 用于治疗自身免疫性病症和炎性病症的作为s1p1受体激动剂的经取代的三环酸衍生物
WO2010085584A1 (en) 2009-01-23 2010-07-29 Bristol-Myers Squibb Company Pyrazole-i, 2, 4 -oxad iazole derivatives as s.phing0sine-1-ph0sphate agonists
WO2010085581A1 (en) 2009-01-23 2010-07-29 Bristol-Myers Squibb Company Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases
WO2010085582A1 (en) 2009-01-23 2010-07-29 Bristol-Myers Squibb Company Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases
KR101409131B1 (ko) 2009-07-16 2014-06-17 액테리온 파마슈티칼 리미티드 피리딘-4-일 유도체
US8399451B2 (en) 2009-08-07 2013-03-19 Bristol-Myers Squibb Company Heterocyclic compounds
CA2786994C (en) 2010-01-27 2018-01-16 Arena Pharmaceuticals, Inc. Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
CN105503882B (zh) 2010-03-03 2019-07-05 艾尼纳制药公司 制备s1p1受体调节剂及其晶体形式的方法
WO2012040532A1 (en) 2010-09-24 2012-03-29 Bristol-Myers Squibb Company Substituted oxadiazole compounds and their use as s1p1 agonists
SG191742A1 (en) 2011-01-19 2013-08-30 Actelion Pharmaceuticals Ltd 2-methoxy-pyridin-4-yl derivatives
IN2015MN00002A (de) 2012-07-09 2015-10-16 Lupin Ltd
SMT202000298T1 (it) 2012-08-17 2020-07-08 Actelion Pharmaceuticals Ltd Processo per la produzione di (2z,5z)-5-(3-cloro-4((r)-2,3-diidrossipropossi) benziliden)-2-(propilimmino)-3-(o-tolil)tiazolidin-4-one e intermedio usato in detto processo
AU2016205361C1 (en) 2015-01-06 2021-04-08 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
MY192358A (en) 2015-05-20 2022-08-17 Idorsia Pharmaceuticals Ltd Crystalline form of the compound (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol
US10111841B2 (en) 2015-06-19 2018-10-30 University Of South Florida Stabilization of alcohol intoxication-induced cardiovascular instability
PL3310760T3 (pl) 2015-06-22 2023-03-06 Arena Pharmaceuticals, Inc. Krystaliczna sól L-argininy kwasu (R)-2-(7-(4-cyklopentylo-3-(trifluorometylo)benzyloksy)- 1,2,3,4-tetrahydrocyklo-penta[b]indol-3-ilo)octowego do zastosowania w zaburzeniach związanych z receptorem S1P1
KR20190116416A (ko) 2017-02-16 2019-10-14 아레나 파마슈티칼스, 인크. 원발 담즙성 담관염을 치료하기 위한 화합물 및 방법
JP2020507610A (ja) 2017-02-16 2020-03-12 アリーナ ファーマシューティカルズ, インコーポレイテッド 腸管外症状を伴う炎症性腸疾患の治療のための化合物および方法
AU2019280822A1 (en) 2018-06-06 2021-01-07 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
EP3847158A1 (de) 2018-09-06 2021-07-14 Arena Pharmaceuticals, Inc. Verbindungen zur verwendung bei der behandlung von autoimmun- und entzündlichen erkrankungen
KR20240018890A (ko) 2022-08-03 2024-02-14 이진수 절개선을 갖는 종이 원단의 연신 특성을 이용한 과일 트레이 제조방법 및 이로부터 제조된 친환경 과일 트레이
KR20240078837A (ko) 2022-11-28 2024-06-04 이진수 폐지를 활용한 임산물 트레이 제조방법 및 이로부터 제조된 친환경 임산물 트레이

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1989480A (en) * 1932-06-27 1935-01-29 Associated Patents Inc Process of preparing cereal foods
US2000615A (en) * 1935-03-04 1935-05-07 Chester H Roth Hosiery
FR2599740B1 (fr) 1986-06-05 1988-08-12 Rhone Poulenc Sante Derives de benzo(b)thiophene de benzo(b)furannecarboxamides, leurs procedes de preparation et les medicaments les contenant
US4963557A (en) 1987-09-28 1990-10-16 Smithkline Beecham Corporation Immunomodulatory azaspiranes
AU7686891A (en) 1990-04-05 1991-10-30 American National Red Cross, The A protein family related to immediate-early protein expressed by human endothelial cells during differentiation
ZA917371B (en) 1990-09-20 1992-06-24 Merrell Dow Pharma Calcium uptake inhibitors
DE19642451A1 (de) * 1996-10-15 1998-04-16 Merck Patent Gmbh Aminothiophencarbonsäureamide
US6423508B1 (en) 1998-03-09 2002-07-23 Smithkline Beecham Corporation Polynucleotide sequences of human EDG-1c
GB9808665D0 (en) 1998-04-23 1998-06-24 Merck Sharp & Dohme Therapeutic compounds
CA2400858A1 (en) * 2000-03-31 2001-10-11 Shokyo Miki Fused heterocyclic derivatives, their production and use
US20040058894A1 (en) 2002-01-18 2004-03-25 Doherty George A. Selective S1P1/Edg1 receptor agonists
ATE441654T1 (de) 2002-01-18 2009-09-15 Merck & Co Inc Edg-rezeptoragonisten
AU2003202994B2 (en) 2002-01-18 2007-11-22 Merck Sharp & Dohme Corp. N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as Edg receptor agonists
JP2005533058A (ja) * 2002-06-17 2005-11-04 メルク エンド カムパニー インコーポレーテッド Edg受容体アゴニストとしての1−((5−アリール−1,2,4−オキサジアゾール−3−イル)ベンジル)アゼチジン−3−カルボキシラートおよび1−((5−アリール−1,2,4−オキサジアゾール−3−イル)ベンジル)ピロリジン−3−カルボキシラート
WO2004035538A1 (en) 2002-10-15 2004-04-29 Merck & Co., Inc. Process for making azetidine-3-carboxylic acid
CA2524867A1 (en) 2003-05-15 2004-12-02 Merck & Co., Inc. 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists
GB0313677D0 (en) 2003-06-13 2003-07-16 Oxford Glycosciences Uk Ltd Novel compound
CN1859908A (zh) * 2003-10-01 2006-11-08 默克公司 作为s1p受体激动剂的3,5-芳基、杂芳基或环烷基取代的-1,2,4-噁二唑类化合物
AU2004299456B2 (en) 2003-12-17 2010-10-07 Merck Sharp & Dohme Corp. (3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists
WO2006010379A1 (en) 2004-07-29 2006-02-02 Actelion Pharmaceuticals Ltd. Novel thiophene derivatives as immunosuppressive agents
KR20080002850A (ko) 2005-03-23 2008-01-04 액테리온 파마슈티칼 리미티드 신규한 티오펜 유도체
BRPI0609668A2 (pt) 2005-03-23 2011-10-18 Actelion Pharmaceuticals Ltd composto, composição farmacêutica, e, uso de um composto
AR057894A1 (es) 2005-11-23 2007-12-26 Actelion Pharmaceuticals Ltd Derivados de tiofeno
KR20080092385A (ko) 2006-01-24 2008-10-15 액테리온 파마슈티칼 리미티드 신규한 피리딘 유도체
GB0601744D0 (en) 2006-01-27 2006-03-08 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
JP2008534490A (ja) 2008-08-28
JP5047941B2 (ja) 2012-10-10
PT1863787E (pt) 2011-07-29
IL186148A (en) 2012-05-31
CA2602474A1 (en) 2006-09-28
KR20080003360A (ko) 2008-01-07
ZA200709088B (en) 2008-09-25
BRPI0609515A2 (pt) 2010-04-13
KR101382733B1 (ko) 2014-04-14
CA2602474C (en) 2014-06-10
US8039644B2 (en) 2011-10-18
HRP20110613T1 (hr) 2011-09-30
ES2365747T3 (es) 2011-10-10
US20080176926A1 (en) 2008-07-24
AU2006226018B2 (en) 2012-07-12
MX2007011670A (es) 2007-11-15
CN101180290B (zh) 2012-12-12
TWI402262B (zh) 2013-07-21
NZ562562A (en) 2010-11-26
RU2412179C2 (ru) 2011-02-20
SI1863787T1 (sl) 2011-10-28
NO20075299L (no) 2007-12-27
IL186148A0 (en) 2008-01-20
AR053452A1 (es) 2007-05-09
EP1863787A1 (de) 2007-12-12
DK1863787T3 (da) 2011-08-01
NO340192B1 (no) 2017-03-20
US7723378B2 (en) 2010-05-25
RU2007138875A (ru) 2009-04-27
US20100204198A1 (en) 2010-08-12
MY147949A (en) 2013-02-15
EP1863787B1 (de) 2011-05-25
PL1863787T3 (pl) 2011-10-31
BRPI0609515A8 (pt) 2017-12-26
CN101180290A (zh) 2008-05-14
WO2006100631A1 (en) 2006-09-28
CY1111767T1 (el) 2015-10-07
AU2006226018A1 (en) 2006-09-28
TW200716591A (en) 2007-05-01

Similar Documents

Publication Publication Date Title
ATE490249T1 (de) Purinderivate als immunmodulatoren
ATE532784T1 (de) 3-deazapurinderivate als tlr7-modulatoren
DK1928882T3 (da) (s)-n-methylnaltrexon
EP1917072A4 (de) Vitaminformulierung
ATE460417T1 (de) Acetylenylpyrazolopyrimidinderivate als mglur2- antagonsten
DK2069335T3 (da) Pyridin-3-ylderivater som immunomoduleringsmidler
DE602007006531D1 (de) Pyrazin-2-carboxamid-derivate als cb2-rezeptormodulatoren
EP1841794A4 (de) Adam-9-modulatoren
DE602006000103D1 (de) Ansaugtraktanordnung
ATE529429T1 (de) Tricyclische spiroderivate als crth2-modulatoren
BRPI0813230A2 (pt) Moduladores de calicreína 7
ATE479676T1 (de) Als antikoagulanzien verwendbare phenylglycinamid-derivate
EP2003131A4 (de) Aminopyrrolidinverbindung
CR10039A (es) Derivados espirocíclicos
DE602006010508D1 (de) Substituierte triazolderivate als oxytocinantagonisten
DE602005022364D1 (de) Selbstbräunendes kosmetikum
DE602006010581D1 (de) 4-phenyl-6-substituierte pyrimidin-2-carbonitrilderivate
ATE485294T1 (de) Azaindol-2-carboxamid-derivate
EP1915162A4 (de) Modulatoren
EP1751115A4 (de) Theramuteinmodulatoren
ATE527255T1 (de) Aryl-isoxazol-4-yl-imidazol-derivate
DE602008003432D1 (de) Substituierte furoä2,3-büpyridinderivate als cannabinoid-1-rezeptormodulatoren
ATE537166T1 (de) Piperidylpropanthiole als ccr3-modulatoren
DE602006015186D1 (de) Oxindole als kinaseinhibitoren
DE602006007832D1 (de) Benzotriazolderivate als cannabinoidrezeptorantagonisten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1863787

Country of ref document: EP